{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:10:59Z","timestamp":1788379859279,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40256-013-0051-2","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T09:48:42Z","timestamp":1383126522000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics, Tolerability, and Safety of the Single Oral Administration of AGSAV301 vs Exforge: A Randomized Crossover Study of Healthy Male Volunteers"],"prefix":"10.1007","volume":"14","author":[{"given":"Hee Youn","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Jo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yook-Hwan","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Hyang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun-Seop","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"issue":"9343","key":"51_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","volume":"360","author":"M Ezzati","year":"2002","unstructured":"Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347.","journal-title":"Lancet"},{"issue":"9455","key":"51_CR2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217.","journal-title":"Lancet"},{"issue":"23","key":"51_CR3","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.jacc.2011.07.045","volume":"58","author":"L Gray","year":"2011","unstructured":"Gray L, Lee IM, Sesso HD, Batty GD. Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality. J Am Coll Cardiol. 2011;58(23):2396.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"51_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","volume":"123","author":"PA Heidenreich","year":"2011","unstructured":"Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933\u201344.","journal-title":"Circulation"},{"issue":"2","key":"51_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.7326\/0003-4819-149-2-200807150-00005","volume":"149","author":"MJ Pletcher","year":"2008","unstructured":"Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med. 2008;149(2):91.","journal-title":"Ann Intern Med"},{"key":"51_CR6","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer HH, de Villiers JN, Sudano I, et al. Recommendations for the treatment of hypertension in the elderly and very elderly: a scotoma within international guidelines. Swiss Med Wkly. Epub 2012 May 9.","DOI":"10.4414\/smw.2012.13574"},{"issue":"6","key":"51_CR7","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206.","journal-title":"Hypertension"},{"issue":"9","key":"51_CR8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens. 2007;25(9):1751.","journal-title":"J Hypertens"},{"issue":"4","key":"51_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12325-008-0042-x","volume":"25","author":"C Ferri","year":"2008","unstructured":"Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther. 2008;25(4):300.","journal-title":"Adv Ther"},{"issue":"9","key":"51_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2165\/11538440-000000000-00000","volume":"30","author":"PM da Silva","year":"2010","unstructured":"da Silva PM. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine\/valsartan. Clin Drug Investig. 2010;30(9):625.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"51_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2165\/00003495-199141030-00009","volume":"41","author":"D Murdoch","year":"1991","unstructured":"Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1991;41(3):478.","journal-title":"Drugs"},{"issue":"2","key":"51_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00003495-199754020-00009","volume":"54","author":"A Markham","year":"1997","unstructured":"Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997;54(2):299.","journal-title":"Drugs"},{"issue":"4","key":"51_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","volume":"29","author":"T Philipp","year":"2007","unstructured":"Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563.","journal-title":"Clin Ther"},{"issue":"5","key":"51_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1524-6175.2007.06689.x","volume":"9","author":"TR Smith","year":"2007","unstructured":"Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9(5):355.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"51_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.amjhyper.2004.02.003","volume":"17","author":"KA Jamerson","year":"2004","unstructured":"Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor\/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17(6):495.","journal-title":"Am J Hypertens"},{"issue":"4","key":"51_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","volume":"30","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587.","journal-title":"Clin Ther"},{"issue":"4","key":"51_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jash.2008.01.004","volume":"2","author":"M Destro","year":"2008","unstructured":"Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine\/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens. 2008;2(4):294.","journal-title":"J Am Soc Hypertens"},{"issue":"12","key":"51_CR18","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1517\/14656560903120899","volume":"10","author":"JM Flack","year":"2009","unstructured":"Flack JM, Hilkert R. Single-pill combination of amlodipine and valsartan in the management of hypertension. Expert Opin Pharmacother. 2009;10(12):1979.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"51_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/10641963.2010.531849","volume":"33","author":"J Huang","year":"2011","unstructured":"Huang J, Sun NL, Hao YM, et al. Efficacy and tolerability of a single-pill combination of amlodipine\/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy. Clin Exp Hypertens. 2011;33(3):179.","journal-title":"Clin Exp Hypertens"},{"issue":"3","key":"51_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1751-7176.2008.07516.x","volume":"10","author":"Y Allemann","year":"2008","unstructured":"Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10(3):185.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"18","key":"51_CR21","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1021\/jm00096a005","volume":"35","author":"S Goldmann","year":"1992","unstructured":"Goldmann S, Stoltefuss J, Born L. Determination of the absolute configuration of the active amlodipine enantiomer as (\u2013)-S: a correction. J Med Chem. 1992;35(18):3341.","journal-title":"J Med Chem"},{"issue":"7","key":"51_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/chir.530060704","volume":"6","author":"H Laufen","year":"1994","unstructured":"Laufen H, Leitold M. Enantioselective disposition of oral amlodipine in healthy volunteers. Chirality. 1994;6(7):531.","journal-title":"Chirality"},{"key":"51_CR23","first-page":"187","volume":"52","author":"L Adik-Pathak","year":"2004","unstructured":"Adik-Pathak L. Chiral molecules in hypertension: focus on S-amlodipine. J Assoc Physicians India. 2004;52:187.","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"51_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clinthera.2010.01.017","volume":"32","author":"BH Kim","year":"2010","unstructured":"Kim BH, Kim JR, Kim MG, et al. Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. Clin Ther. 2010;32(1):193.","journal-title":"Clin Ther"},{"issue":"5","key":"51_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.clinthera.2008.05.013","volume":"30","author":"SA Kim","year":"2008","unstructured":"Kim SA, Park S, Chung N, et al. Efficacy and safety profiles of a new S(\u2013)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial. Clin Ther. 2008;30(5):845.","journal-title":"Clin Ther"},{"issue":"8","key":"51_CR26","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1185\/03007990802262457","volume":"24","author":"JM Neutel","year":"2008","unstructured":"Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin. 2008;24(8):2389.","journal-title":"Curr Med Res Opin"},{"key":"51_CR27","first-page":"1765","volume":"22","author":"T Jung","year":"2001","unstructured":"Jung T, Hwang S, Lee J, Jo M, Kim Y, Yoo T. Comparative consistency between obesity determination standards using body mass index and ideal body weight. J Korean Acad Fam Med. 2001;22:1765.","journal-title":"J Korean Acad Fam Med"},{"key":"51_CR28","unstructured":"WMA. Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. 59th WMA General Assembly, Seoul, October 2008. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/17c.pdf (Accessed 30 Sep 2013)."},{"key":"51_CR29","unstructured":"FDA. Guidance for industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM); 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf (Accessed 30 Sep 2013)."},{"key":"51_CR30","unstructured":"KFDA. Guidance for the Validation of Bioanalytical Method (Korean); 2010. http:\/\/www.mfds.go.kr\/index.do?searchkey=notice_number&mid=560&searchword=B1-2010-2-016&pageNo=1&seq=4531&cmd=v (Accessed 30 Sep 2013)."},{"key":"51_CR31","volume-title":"Pharmacokinetic & pharmacodynamic data analysis: concepts and applications","author":"J Gabrielsson","year":"2006","unstructured":"Gabrielsson J, Weiner D. Pharmacokinetic & pharmacodynamic data analysis: concepts and applications. 4th ed. Stockholm: The Swedish Pharmaceutical Press; 2006.","edition":"4"},{"issue":"8","key":"51_CR32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/jps.2600610845","volume":"61","author":"WJ Westlake","year":"1972","unstructured":"Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci. 1972;61(8):1340.","journal-title":"J Pharm Sci"},{"issue":"Suppl 1","key":"51_CR33","first-page":"S45","volume":"30","author":"VW Steinijans","year":"1992","unstructured":"Steinijans VW, Hauschke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992;30(Suppl 1):S45.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"51_CR34","unstructured":"Chow S, Liu H. Design and analysis of bioavailability and bioequivalence studies. New York Marcel Dekker Inc; 1992."},{"issue":"2","key":"51_CR35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1042\/bst0190472","volume":"19","author":"DB Campbell","year":"1991","unstructured":"Campbell DB, Wilson K. Chirality and its importance in drug development. Biochem Soc Trans. 1991;19(2):472.","journal-title":"Biochem Soc Trans"},{"key":"51_CR36","doi-asserted-by":"crossref","unstructured":"FDA\u2019s policy statement for the development of new stereoisomeric drugs. Chirality. 1992;4(5):338.","DOI":"10.1002\/chir.530040513"},{"issue":"4","key":"51_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/bja\/88.4.563","volume":"88","author":"D Burke","year":"2002","unstructured":"Burke D, Henderson DJ. Chirality: a blueprint for the future. Br J Anaesth. 2002;88(4):563.","journal-title":"Br J Anaesth"},{"issue":"11","key":"51_CR38","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.clinthera.2006.11.008","volume":"28","author":"JY Park","year":"2006","unstructured":"Park JY, Kim KA, Park PW, et al. Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. Clin Ther. 2006;28(11):1837.","journal-title":"Clin Ther"},{"issue":"11","key":"51_CR39","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1586\/erc.10.144","volume":"8","author":"M Camafort-Babkowski","year":"2010","unstructured":"Camafort-Babkowski M. Choosing an antihypertensive combination with a more efficient central blood pressure reduction. Expert Rev Cardiovasc Ther. 2010;8(11):1523.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"51_CR40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/0091270010376963","volume":"51","author":"P Bhad","year":"2011","unstructured":"Bhad P, Ayalasomayajula S, Karan R, et al. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. J Clin Pharmacol. 2011;51(6):933.","journal-title":"J Clin Pharmacol"},{"issue":"12 Pt 1","key":"51_CR41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/009127000004001206","volume":"40","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CA. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1347.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"51_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2165\/11201120-000000000-00000","volume":"9","author":"JE Frampton","year":"2009","unstructured":"Frampton JE, Scott LJ. Amlodipine\/valsartan single-pill combination: a review of its use in the management of hypertension. Am J Cardiovasc Drugs. 2009;9(5):309.","journal-title":"Am J Cardiovasc Drugs"},{"key":"51_CR43","first-page":"1","volume":"4","author":"JM Krzesinski","year":"2010","unstructured":"Krzesinski JM, Cohen EP. Exforge (amlodipine\/valsartan combination) in hypertension: the evidence of its therapeutic impact. Core Evid. 2010;4:1.","journal-title":"Core Evid"},{"key":"51_CR44","unstructured":"EMEA. European Public Assessment Report (EPAR) Exforge http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000716\/WC500033004.pdf (Accessed 24 June 2013)."},{"issue":"5","key":"51_CR45","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.phrs.2004.11.006","volume":"51","author":"F Abad-Santos","year":"2005","unstructured":"Abad-Santos F, Novalbos J, Galvez-Mugica MA, et al. Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. Pharmacol Res. 2005;51(5):445.","journal-title":"Pharmacol Res"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0051-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-013-0051-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0051-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0051-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T20:38:08Z","timestamp":1688589488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-013-0051-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s40256-013-0051-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]},"assertion":[{"value":"31 October 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}